Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or Metastatic renal cell carcinoma (RCC)~* Predominant clear cell histology:~  1. At least 1 but no more than 2 prior systemic anti vascular endothelial growth factor (anti-VEGF) treatments~ 2. No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting~ 3. Subjects with prior treatment with a mechanistic target of rapamycin (mTOR) are eligible~* Non-clear cell histology: 0-3 prior systemic therapies and may include mTOR inhibitor~* Brain metastases allowed if asymptomatic, without edema, and not receiving corticosteroids or radiation~* Performance Status (PS): ≥ 70% Karnofsky Performance Scale (KPS)~* All Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic scores allowed~Exclusion Criteria:~* Subjects with any active autoimmune disease or a history of known autoimmune disease~* History of severe hypersensitivity reaction to other monoclonal antibodies~* Prior malignancy, active within the last 3 years, except for locally curable cancers which have been apparently cured~* Known HIV or AIDS-related illness~* Any positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infection~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: EXPERIMENTAL): Nivolumab dose as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).